Get the RNN Research Report and
Also Receive Our Top Trades for 2017!

Rexahn Pharmaceuticals, Inc.

Rexahn’s cash and investments totaled approximately $20.3 million as of December 31, 2016, compared to approximately $23.4 million as of December 31, 2015. Rexahn expects that its cash and investments as of December 31, 2016 will be sufficient to fund the company’s cash flow requirements for its current activities through the first half of 2018. Research and development expenses were $10.1 million for the year ended December 31, 2016, compared to $12.1 million for the year ended December 31, 201 … (See Research Report)
Download Research Report
on RNN Now